Harvard Bioscience Inc.
2.02
0.04 (2.02%)
At close: Jan 14, 2025, 3:59 PM
2.02
0.25%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 1.96
Market Cap 87.89M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.33
PE Ratio (ttm) -6.11
Forward PE n/a
Analyst Strong Buy
Ask 2.06
Volume 154,257
Avg. Volume (20D) 189,140
Open 2.00
Previous Close 1.98
Day's Range 1.96 - 2.06
52-Week Range 1.81 - 4.93
Beta undefined

About HBIO

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgic...

Sector Healthcare
IPO Date Mar 19, 2001
Employees 391
Stock Exchange NASDAQ
Ticker Symbol HBIO

Analyst Forecast

According to 2 analyst ratings, the average rating for HBIO stock is "Strong Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Harvard Bioscience Inc. is scheduled to release its earnings on Mar 6, 2025, before market opens.
Analysts project revenue of $24.15M, reflecting a -14.22% YoY shrinking and earnings per share of 0.05, making a 25.00% increase YoY.